Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 5Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Refractory Solid Tumors 1Liposarcoma 1HR+HER2- Breast Cancer 1Carcinoma, Transitional Cell 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Doxorubicin 4pembrolizumab 3Radiotherapy 3Radiation 3Biopsy 3pazopanib 2palbociclib 2abemaciclib 2Immunoglobulin G 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1silmitasertib 1selinexor 1ribociclib 1peposertib 1mirdametinib 1liposomal doxorubicin 1eribulin 1durvalumab 1cemiplimab 1X-Rays 1Vincristine 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × eribulin × 90 days × Clear all
NCT03361436 2026-04-08

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

OHSU Knight Cancer Institute

Phase 1 Active not recruiting
15 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡